Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.370 -0.040 (-2.84%)
Delayed Quote Updated: 1:45 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OS Therapies Incorporated Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company preparing to complete submissions for... 
Via Newsfile
News headline image
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate... 
Via Newsfile
News headline image
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
New York, New York and Rockville, Maryland--(Newsfile Corp. - September 24, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS... 
Via Newsfile
News headline image
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
Recent U.K. MHRA Scientific Advice Meeting (SAM) that resulted in full alignment to initiate confirmatory Phase 3 trial in U.K.... 
Via Newsfile
News headline image
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
FDA aligns with MHRA and EMA on adaptive design for Phase 3 trialAfter successful Scientific Advice Meeting, Company accepts MHRA... 
Via Newsfile
News headline image
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
Overall Survival (OS) historical-control data gains HMRA and EMA support for pending CMAA submissionsFull alignment achieved on confirmatory Phase 3... 
Via Newsfile
OS Animal Health Featured in Coverage of the Disruptive Growth & Life Sciences Conference
Via Investor Brand Network
News headline image
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
71.2% 3-year overall survival for OST-HER2-treated patients vs. 45.8% comparable combined historical control (p = 0.002)The two remaining patients who... 
Via Newsfile
InvestorNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push
Via Investor Brand Network
News headline image
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
Management will participate at Jefferies Global Healthcare Conference, H.C. Wainwright Global Investment Conference, ROTH Healthcare Opportunities Conference Management and business... 
Via Newsfile
News headline image
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million... 
Via Newsfile
News headline image
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret... 
Via Newsfile
News headline image
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
New York, New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Third Quarter 2026 Corporate Outlook
New York, New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS... 
Via Newsfile
News headline image
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
Company secures $10 million line of credit supported by OS Therapies UK tax creditsNew York, New York and Rockville, Maryland--(Newsfile... 
Via Newsfile
News headline image
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods... 
Via Newsfile
News headline image
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
20% of OST-HER2 treated dogs survived 2-year vs. 1% in control group (p = 0.00995)Over 15,000 dogs per year diagnosed... 
Via Newsfile
News headline image
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control ... 
Via Newsfile
Topics Death Intellectual Property
News headline image
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the... 
Via Newsfile
News headline image
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference:... 
Via Newsfile
News headline image
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to... 
Via Newsfile
Topics Regulatory Compliance
News headline image
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS... 
Via Newsfile
News headline image
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S.,... 
Via Newsfile
News headline image
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX)
Dallas, Texas--(Newsfile Corp. - May 12, 2026) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage... 
Via Newsfile
News headline image
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma
Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response... 
Via Newsfile
News headline image
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET
Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular... 
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
Co-founder of more than 40 biotechnology companies, including 16 IPOs and 19 successful acquisitions Scientific and medical titan focused on... 
Via Newsfile
News headline image
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX
From The Rosen Law Firm, P.A.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.